ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
EMA’s PRAC to review Xeljanz and recommends fenspiride withdrawl pharmatimes
May 20, 2019The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has announced its latest meeting highlights, including a restriction of the use of Xeljanz (tofacitinib), and a call for withdrawal of?marketing authorisations for fe
Pharma Sources Insight January 2025
